#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS

Continuous monitoring of blood glucose in diabetes mellitus management – aid in individualization of treatment

Czech version

Authors: Dana Prídavková;  Udovít Šutarík;  Peter Galajda;  Marián Mokáň
Authors‘ workplace: I. Interná klinika JLF UK a UN Martin
Published in: Forum Diab 2019; 8(3): 213-219
Category:

Overview

Continuous glucose monitoring (CGM) is a method of recording blood glucose in interstitial fluid via a subcutaneous sensor with some time delay beyond the blood glucose determined by the bloodstream. It represents a diagnostically valuable modality that promotes patient cooperation, motivation and interest in the development of their disease. It provides doctors with information on glycemic development during the period under review and is also an essential component in the functioning of modern insulin pumps of the AID (automated insulin delivery) nature.

Keywords:

hyperglycemia – glucose variability – hypoglycemia – continuous glucose monitoring

Sources
  1. Nathan DM, Genuth S, Lachin J et al. [Diabetes Control and Complications Trial Research Group]. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977–986. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM199309303291401>.
  2. Nathan DM. [DCCT/EDIC Research Group]. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014; 37(1): 9–16. Dostupné z DOI: <http://dx.doi.org/ 10.2337/dc13–2112>.
  3. [UK Prospective Diabetes Study (UKPDS) Group]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998; 352(9131): 854–865. Erratum in Lancet 1998; 352(9139): 1558.
  4. Gerstein HC, Miller ME, Byington PR et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24): 2545–2559. Dostupné z DOI: <http://dx.doi.org/ 10.1056/NEJMoa0802743>.
  5. Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909. Dostupné z DOI: <https://dx.doi.org/10.1136/bmj.b4909 >.
  6. Ali MK, McKeever Bullard K, Imperatore G et al. Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes-National Health and Nutrition Examination Survey, United States, 2007–2010. MMWR Suppl 2012; 61(2): 32–37.
  7. Ford ES. Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: findings from the National Health and Nutrition Examination Survey 1999–2008*. J Diabetes 2011; 3(4): 337–347. Dostupné z DOI: <http://dx.doi.org/ 10.1111/j.1753–0407.2011.00148.x>.
  8. Miller KM, Foster NC, Beck RW et al. [T1D Exchange Clinic Network]. Current state of type 1 diabetes treatment in the U. S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015; 38(6): 971–978. Dostupné z DOI: <http://doi: 10.2337/dc15–0078>.
  9. Krhač M, Lovrenčić MV. Update on biomarkers of glycemic control. World J Diabetes 2019; 10(1): 1–15. Dostupné z DOI: <http://dx.doi.org/10.4239/wjd.v10.i1.1>.
  10. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes – 2019 Diabetes Care 2019; 42(Suppl 1): S61-S70 Dostupné z DOI: <http://dx.doi.org/10.2337/dc19-S006>.
  11. Pani LN, Korenda L, Meigs JB et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001–2004. Diabetes Care 2008; 31(10): 1991–1996. Dostupné z DOI: <http://dx.doi.org/ 10.2337/dc08–0577>.
  12. Cavagnolli G, Pimentel AL, Freitas PA et al. Effect of ethnicity on HbA1c levels in individuals without diabetes: Systematic review and meta-analysis. PLoS One 2017; 12(2): e0171315. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0171315.
  13. Wheeler E, Leong A, Liu CT et al. [EPIC-CVD Consortium; EPIC-InterAct Consortium; Lifelines Cohort Study]. Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. PLoS Med 2017; 14(9): e1002383. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pmed.1002383>.
  14. Berard LD, Siemens R, Woo V. [Diabetes Canada Clinical Practice Guidelines Expert Committee]. Monitoring Glycemic Control. Can J Diabetes 2018; 42(Suppl 1): S47-S53. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcjd.2017.10.007>.
  15. Ekhlaspour L, Mondesir D, Lautsch N et al. Comparative Accuracy of 17 Point-of-Care Glucose Meters. J Diabetes Sci Technol 2017; 11(3): 558–566. Dostupné z DOI: <http://dx.doi.org/10.1177/1932296816672237>.
  16. [Consensus Committee]. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007; 30(9): 2399–2400. Dostupné z DOI: <http://dx.doi.org/10.2337/dc07–9925>.
  17. Sheppard P, Bending JJ, Huber JW. Pre- and post-prandial capillary glucose selfmonitoring achieves better glycaemic control than pre-prandial only monitoring. Pract Diab Int 2005; 22(1): 15–22. Dostupné z DOI: <http://dx.doi.org/10.1002/pdi.733>.
  18. Malanda UL, Welschen LM, Riphagen II et al. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev 2012;(1) :CD005060. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD005060.pub3>.
  19. Acciaroli G, Vettoretti M, Facchinetti A et al. Calibration of minimally invasive continuous glucose monitoring sensors: state-of-the-art and current perspectives. Biosensors (Basel) 2018; 8(1): E24. Dostupné z DOI: <http://dx.doi.org/10.3390/bios8010024>.
  20. Kropff J, Choudhary P, Neupane S et al. Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial. Diabetes Care 2017; 40(1): 63–68. Dostupné z DOI: <http://dx.doi.org/:10.2337/dc16–1525>.
  21. Rodbard D. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes. Diabetes Technol Ther 2017; 19(S3): S25-S37. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2017.0035>.
  22. Beck RW, Riddlesworth T, Ruedy K et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 2017;317(4): 371–378. Dostupné z DOI: <<http://dx.doi.org/ 10.1001/jama.2016.19975>>.
  23. Lind M, Polonsky W, Hirsch IB et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017; 317(4): 379–387. Dostupné z DOI: <http://dx.doi.org.doi/10.1001/jama.2016.19976>. Erratum in Incorrect Unit of Measure. [JAMA. 2017].
  24. Luo P, Cheng Q, Chen B et al. Hypoglycemia and blood glucose fluctuations in the application of a sensor-augmented insulin pump. Diabetes Technol Ther 2013; 15(12): 984–989. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2013.0078>.
  25. Bergenstal RM, Tamborlane WV, Ahmann A et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363(4): 311–320. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1002853>. Erratum in N Engl J Med 2010; 363(11): 1092.
  26. Hermanides J, Norgaard K, Bruttomesso D et al. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled type 1 diabetes; a randomized controlled trial. Diabet Med 2011; 28(10): 1158–1167. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1464–5491.2011.03256.x>.
  27. Raccah D, Sulmont V, Reznik Y et al.Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the realtrend study. Diabetes Care 2009; 32(12): 2245–2250. Dostupné z DOI: <http://dx.doi.org/10.2337/dc09–0750>.
  28. Zucchini S, Scipione M, Balsamo C et al. Comparison between sensor-augmented insulin therapy with continuous subcutaneous insulin infusion or multiple daily injections in everyday life: 3-day analysis of glucose patterns and sensor accuracy in children. Diabetes Technol Ther 2011; 13(12): 1187–1193. Dostupné z DOI: <<http://dx.doi.org/ 10.1089/dia.2011.0080>>.
  29. Buckingham B, Cobry E, Clinton P et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther 2009; 11(2): 93–97. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2008.0032>.
  30. Choudhary P, Olsen BS, Conget I et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016; 18(5): 288–291. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2015.0324>.
  31. Peyrot M, Rubin RR. [STAR 3 Study Group]. Treatment satisfaction in the sensor-augmented pump therapy for A1c reduction 3 (STAR 3) trial. Diabet Med 2013; 30(4): 464–467. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.12079>.
  32. Sharifi A, De Bock MI, Jayawardene D et al. Glycemia, treatment satisfaction, cognition, and sleep quality in adults and adolescents with type 1 diabetes when using a closed-loop system overnight versus sensor-augmented pump with low-glucose suspend function: a randomized crossover study. Diabetes Technol Ther 2016; 18(12): 772–783. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2016.0288>.
  33. Roze S, Saunders R, Brandt AS et al. Health-economic analysis of real-time continuous glucose monitoring in people with type 1 diabetes. Diabet Med 2015; 32(5): 618–626. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.12661>.
  34. Hirsch IB. Glycemic variability and diabetes complications: does it matter? Of course it does! Diabetes Care 2015; 38(8): 1610–1614. Dostupné z DOI: <http://dx.doi.org/10.2337/dc14–2898>.
  35. Gorst C, Kwok CS, Aslam S et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care 2015; 38(12): 2354–2369. Dostupné z DOI: <http://dx.doi.org/ 10.2337/dc15–1188>.
  36. Tamborlane WV, Beck RW, Bode BW et al. [Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group]. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359(14): 1464–1476. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0805017>.
  37. [Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group]. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabetes Care 2010; 33(1): 17–22. Dostupné z DOI: <http://dxl.doi.org/10.2337/dc09–1502>.
  38. Ceriello A, Espisto L, Piconi L et al. Oscilating gluoces is more deletrious to endothelial function and oxidative stress than mean glucose Diabetes 2008; 57(5): 1349–1354. Dostupné z DOI: <http://dx.doi.org/10.2337/db08–0063>.
  39. Chehregosha H, Khamseh ME, Malek M et al. A View Beyond HbA1c: Role of Continuous Glucose Monitoring. Diabetes Ther 2019; 10(3): 853–863. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–019–0619–1>.
  40. Clarke SF, Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci 2012; 69(2): 83–93.
  41. Bailey TS. Clinical implications of accuracy measurements of continuous glucose sensors. Diabetes Technol Ther 2017; 19(S2): S51–S54. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2017.0050>.
  42. Bailey TS, Ahmann A, Brazg R et al. Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor. Diabetes Technol Ther 2014; 16(5): 277–283. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2013.0222>.
  43. Zisser HC, Bailey TS, Schwartz S et al. Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements. J Diabetes Sci Technol 2009; 3(5): 1146–1154. Dostupné z DOI: <http://dx.doi.org/ 10.1177/193229680900300519>.
  44. Weinstein RL, Schwartz SL, Brazg RL et al. Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care 2007; 30(5): 1125–1130. Dostupné z DOI: <http://dxl.doi.org/0.2337/dc06–1602>.
  45. Christiansen M, Bailey T, Watkins E et al. A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system. Diabetes Technol Ther 2013; 15(10): 881–888. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2013.0077>.
  46. Bailey TS, Chang A, Christiansen M. Clinical accuracy of a continuous glucose monitoring system with an advanced algorithm. J Diabetes Sci Technol 2015; 9(2): 209–214. Dostupné z DOI: <http://dx.doi.org/10.1177/1932296814559746>.
  47. Geoffrey M, Brazg R, Richard W. FreeStyle Navigator Continuous Glucose Monitoring System with TRUstart algorithm, a 1-hour warm-up time. J Diabetes Sci Technol 2011; 5(1): 99–106. Dostupné z DOI: <http://dx.doi.org/10.1177/193229681100500114>.
  48. Dexcom Inc. FDA authorizes marketing of the new Dexcom G6 CGM eliminating the need for fingerstick blood testing for people with diabetes. 2018. Dostupné z WWW: <https://www.dexcom.com/news/fda-authorizes-dexcom-g6>.
  49. Medtronic. Manage glucose levels with a smarter CGM (Continuous Glucose Monitoring) system, powered by Guardian™ Sensor 3. Dostupné z WWW: <https://professional.medtronicdiabetes.com/guardian-sensor-3>.
  50. Bergenstal RM, Garg S, Weinzimer SA et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 2016; 316(13): 1407–1408. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.11708>.
  51. Trevitt S, Simpson S, Wood A. Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development? J Diabetes Sci Technol 2016; 10(3): 714–723. Dostupné z DOI: <http://dx.doi.org/10.1177/1932296815617968>.
  52. Aleppo G, Webb K. Intergrated insulin pump and continuous glucose monitoring technology in diabetes care today: a perspective of real-life experience with the Minimed™ 670G hybrid closed-loop system. Endocr Pract 2018; 24(7): 684- 692. Dostupné z DOI: <http://dx.doi.org/10.4158/EP-2018–0097>.
  53. [U.S. Food and Drug Administration]. Guidance for Industry and Food and Drug Administration Staff The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems. November 9, 2012. Dostupné z WWW: <https://www.fda.gov/media/80644/download>.
  54. Heinemann L, Stuhr A, Brown A et al. Self-measurement of Blood Glucose and Continuous Glucose Monitoring – Is There Only One Future? Eur Endocrinol 2018; 14(2): 24–29. Dostupné z DOI: <http://dxl.doi.org/10.17925/EE.2018.14.2.24>.
  55. Bailey T, Bode BW, Christiansen MP et al. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther 2015; 17(11): 787–794. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2014.0378>.
  56. U.S. Food and Drug Admistration. Continuous Glucose Monitoring System – P160048/S006. Dostupné z WWW: https://www.fda.gov/medical-devices/recently-approved-devices/eversense-continuous-glucose-monitoring-system-p160048s006>.
  57. Freckmann G. New technologies in diabetology. How far are we from a closed loop? Internist (Berl) 2015; 56(5): 484–492. Dostupné z DOI: <http://dx.doi.org/10.1007/s00108–014–3627–2>.
  58. Sinha M, McKeon KM, Parker S et al. A comparison of time delay in three continuous glucose monitors for adolescents and adults. J Diabetes Sci Technol 2017; 11(6): 1132–1137. Dostupné z DOI: <http://dx.doi.org/10.1177/1932296817704443>.
  59. Danne T, Nimri R, Battelino T et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017; 40(12): 1631–1640. Dostupné z DOI: <http://dx.doi.org/10.2337/dc17–1600>.
  60. Battelino T, Danne T, Bergenstal RM et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time Range. Diabetes Care 2019; 42(8): 1593–1603. Dostupné z DOI: <http://dx.doi.org/10.2337/dci19–0028>.
  61. Šoupal J. Glukózové senzory v léčbě diabetu. Prakt Lékáren 2018; 14(4e):e10-e17.
  62. Carlson AL, Mullen DM, Bergenstal RM et al. Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes. Diabetes Technol Ther 2017; 19(Suppl 2): S4–S11. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2017.0024>.
  63. Medtronic. Systém na reguláciu liečby CareLinktm. Dostupné z WWW: https://www.medtronic-diabetes.sk/minimed-system/softver-na-riadenie-liecby.
  64. Ministerstvo zdravotníctva SR. Zoznam kategorizovaných zdravotníckych pomôcok k 1.10.2019. Dostupné z WWW: www.health.gov.sk.
Labels
Diabetology Endocrinology Internal medicine
Diabetic cardiomyopathy and heart failure
What is actually the cardiovascular risk related to type 2 diabetes?
Cardiorenal syndrome and gliflozins
Obesity, diabetes mellitus and cardiovascular disease: dangerous metabolic triad
The role of a fixed-ratio titratable combination of iGlarLixi in type 2 diabetes mellitus therapeutic regimen
The EMPRISE study (Real World Evidence): empagliflozin is reducing number of hospitalizations for heart failure, even in patients without cardiovascular disease
Cardiovascular studies and gliflozins
Dulaglutide and cardiovascular outcomes in patients with type 2 diabetes: REWIND study
Article was published in

Forum Diabetologicum

Issue 3
2019 Issue 3
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#